The DOI matches its Crossref record.
5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review
Abstract
Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD) treated with 5-aminosalicylic acid (5-ASA). Studies with 5-ASA treatment in which serum creatinine or creatinine clearance was measured regularly show that nephrotoxicity is exceptional (mean rate of only 0.26% per patient-year). There have been several case reports, including 46 patients, of renal disease associated with 5-ASA treatment in patients with IBD. 5-ASA treatment-related nephrotoxicity is reported most often within the first 12 months, but also delayed presentation after several years has been shown. The absence of a clear relationship between 5-ASA dose and the risk of nephrotoxicity suggests that this complication is idiosyncratic rather than dose-related. Most of the patients with renal disease associated with 5-ASA treatment suffered interstitial nephritis, with symptoms and signs being nonspecific, which may delay detection for many months. The nephrotoxicity potential of mesalazine and sulfasalazine seems to be similar. The risk with different oral preparations of 5-ASA is probably too small to influence the choice of agent. Mesalazine should be withdrawn when renal impairment manifests in a patient with IBD; if this does not result in a fall in serum creatinine, then renal biopsy should be considered. A trial of high-dose steroid may be recommended in patients whose renal function does not respond to drug withdrawal. The optimal monitoring schedule of serum creatinine in patients receiving 5-ASA treatment remains to be established, as there is no evidence to date that either the test, or the frequency of testing, improves patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
Drug-induced acute interstitial nephritis
Perazella, M. A., & Markowitz, G. S. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.71 · Cited by 378
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.58 · Cited by 310
Systematic review with meta-analysis: inflammatory bowel disease in the elderly
Gisbert, J. P., & Chaparro, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12616 · Cited by 158
Self-citationPraga, M., Sevillano, A., Auñón, P., & González, E. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu326 · Cited by 147
Metadata
- Authors
- Gisbert, J. P., González-Lama, Y., & Maté, J.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05
- Volume
- 13
- Issue
- 5
- Pages
- 629-638
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2120486443
- Cited by
- 220
- References
- 0
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review. https://app.cochat.ai/papers/10.1002/ibd.20099
- The paper
- Gisbert, J. P., González-Lama, Y., & Maté, J. (2007). 5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review. Inflammatory Bowel Diseases. https://doi.org/10.1002/ibd.20099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.